Strata Critical Medical's Days Sales Outstanding for the
three
months ended in Mar. 2026 was 53.87.
Strata Critical Medical's Days Inventory for the
three
months ended in Mar. 2026 was 0.
Strata Critical Medical's Days Payable for the
three
months ended in Mar. 2026 was 0.
Therefore, Strata Critical Medical's Cash Conversion Cycle (CCC) for the
three
months ended in Mar. 2026 was 53.87.
Strata Critical Medical (NAS:SRTA) Cash Conversion Cycle Explanation
Generally, the lower this number is, the better for the company. Although it should be combined with other metrics (such as ROE % and ROA %), it can be especially useful for comparing close competitors, because the company with the lowest CCC is often the one with better management.
Be Aware
CCC is most effective with retail-type companies, which have inventories that are sold to customers. Consulting businesses, software companies and insurance companies are all examples of companies for whom this metric is meaningless.
The CCC is one of several tools that can help you evaluate management, especially if it is calculated for several consecutive time periods and for several competitors. Decreasing or steady CCCs are good, while rising ones should motivate you to dig a bit deeper.
Strata Critical Medical Cash Conversion Cycle Related Terms
Strata Critical Medical Cash Conversion Cycle Historical Data
* Premium members only.
The historical data trend for Strata Critical Medical's Cash Conversion Cycle can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Strata Critical Medical Cash Conversion Cycle Chart
SRTA vs CYH, CCRN, AUNA: Cash Conversion Cycle Comparison
For the Medical Care Facilities subindustry, Strata Critical Medical's Cash Conversion Cycle, along with its competitors' market caps and Cash Conversion Cycle data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Strata Critical Medical Cash Conversion Cycle vs Healthcare Providers & Services Industry
For the Healthcare Providers & Services industry and Healthcare sector, Strata Critical Medical's Cash Conversion Cycle distribution charts can be found below:
* The bar in red indicates where Strata Critical Medical's Cash Conversion Cycle falls into.
Strata Critical Medical Cash Conversion Cycle Calculation
Cash Conversion Cycle (CCC) measures how fast a company can convert cash on hand into even more cash on hand. This metric looks at the amount of time needed to sell inventory, the amount of time needed to collect receivables and the length of time the company is afforded to pay its bills without incurring penalties.
Cash Conversion Cycle is one of several measures of management effectiveness.
Strata Critical Medical's Cash Conversion Cycle for the fiscal year that ended in Dec. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Strata Critical Medical (SRTA) has a Cash Conversion Cycle of 53.87 as of Mar. 2026. Cash conversion cycle equals sum of days inventory and days sales outstanding less days payable. View historical data on Strata Critical Medical and its competitors.
Is Strata Critical Medical's Cash Conversion Cycle too high?
Strata Critical Medical's current Cash Conversion Cycle is 53.87. The Healthcare Providers & Services industry median Cash Conversion Cycle is 18.21. Strata Critical Medical's value of 53.87 is 195.8% above this industry median. Overall, Strata Critical Medical has a GF Score™ of 70/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Strata Critical Medical's Cash Conversion Cycle compare to CYH and CCRN?
Strata Critical Medical's Cash Conversion Cycle of 53.87 can be compared against companies in the Healthcare Providers & Services industry. The industry median Cash Conversion Cycle is 18.21. Strata Critical Medical's value of 53.87 is 195.8% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cash Conversion Cycle for a Healthcare Providers & Services company?
The median Cash Conversion Cycle among Healthcare Providers & Services companies is 18.21, based on 664 companies in the industry. Companies in the top quartile (top 25%) have a Cash Conversion Cycle significantly above this median, while those in the bottom quartile fall well below. However, Cash Conversion Cycle should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Strata Critical Medical's current Cash Conversion Cycle of 53.87 is 195.8% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cash Conversion Cycle mean?
A high Cash Conversion Cycle can signal that a stock is expensive relative to its fundamentals. Cash conversion cycle equals sum of days inventory and days sales outstanding less days payable. View historical data on Strata Critical Medical and its competitors. For the Healthcare Providers & Services industry, the median Cash Conversion Cycle is 18.21 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Strata Critical Medical's current Cash Conversion Cycle is 53.87. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Strata Critical Medical stock overvalued right now?
Based on GuruFocus' analysis, Strata Critical Medical (SRTA) is currently considered Modestly Overvalued. The stock's GF Value™ is $4.47, compared to a current price of $5.27 — trading 17.8% above its estimated fair value. The current Cash Conversion Cycle is 53.87 and 195.8% above the Healthcare Providers & Services industry median of 18.21. Strata Critical Medical's overall GF Score™ is 70/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cash Conversion Cycle calculated?
Cash Conversion Cycle is calculated from a company's financial statements. For Strata Critical Medical (SRTA), the current Cash Conversion Cycle is 53.87 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Strata Critical Medical (SRTA) Overvalued in 2026?
Based on GuruFocus' analysis, Strata Critical Medical stock appears to be overvalued.
The current stock price of $5.27 is trading 17.8% above its estimated GF Value™ of $4.47.
GuruFocus considers Strata Critical Medical to be Modestly Overvalued.
Key valuation signals for SRTA:
Cash Conversion Cycle: 53.87
GF Value™: $4.47 vs. price of $5.27 (17.8% above fair value)
Industry Position: 195.8% above the Healthcare Providers & Services median
No single metric tells the full story. See the SRTA stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Strata Critical Medical Inc is a time-critical logistics and medical services provider to the U.S. healthcare industry. The group operates one of the nation's air transport and surgical services networks for transplant hospitals and organ procurement organizations, offering an integrated 'One Call' solution for donor organ recovery. It includes two segments: Logistics segments which hold, Air Logistics, Ground Logistics and Organ Placement. The second segment is Clinical Segment which includes: Organ Recovery, Normothermic Regional Perfusion (NRP), and Preservation, and Other Clinical Segment which has Cardiac Care, and Other.
70GF Score
Get the complete analysis for SRTA
Cash Conversion Cycle is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
SRTA has been successfully added to your 
